RNA has emerged as a major player in most cellular processes. Understanding these processes at the molecular level requires homogeneous RNA samples for structural, biochemical and pharmacological studies. So far, this has been a bottleneck, as the only methods for producing such pure RNA have been in vitro syntheses. Here we describe a generic approach for expressing and purifying structured RNA in Escherichia coli, using tools that parallel those available for recombinant proteins. Our system is based on a camouflage strategy, the 'tRNA scaffold', in which the recombinant RNA is disguised as a natural RNA and thus hijacks the host machinery, escaping cellular RNases. This opens the way to large-scale structural and molecular investigations of RNA function.
Systematic studies of protein structure, function and interactions such as structural genomics and double-hybrid approaches have greatly benefited from the development of efficient recombinant expression systems. During this time new roles have been evidenced for structured RNA in translation, chromosome maintenance, viral replication, as riboswitches or ribozymes [1] [2] [3] . As a result, these RNAs are considered to be promising drug targets, as for instance bacterial rRNA (antibiotics) or telomerase RNA 4 . Owing to their large structural repertoire, folded RNAs are also interesting molecules for constructing self-assembling nano-objects, some of which have been used for delivering therapeutic siRNAs 5, 6 .
As opposed to proteins, systematic biochemical, structural and pharmacological studies of RNA have, however, been hampered by difficulties in obtaining homogeneous samples in large quantities. So far, RNA has mostly been produced in vitro using either T7 RNA polymerase transcription 7 or chemical synthesis 8 , which are costly and cumbersome. Producing recombinant RNA in vivo could be an alternative, but thus far has been plagued by obstacles, such as heterogeneity of the products, degradation by RNases and difficulty in purifying the RNA from cell extracts. For example, RNA transcripts overexpressed in vivo using the T7 system 9 are long and heterogeneous, as a consequence of terminator readthrough, and have never been purified. The 5S ribosomal RNA 10 and tRNAs [11] [12] [13] [14] are two exceptions that have been successfully expressed in E. coli. In the latter case, it works because tRNAs are recognized by cellular enzymes that precisely process the primary transcript, incorporate modified nucleotides and repair their 3¢ end 15 . This results in a single product of defined length, a key feature for structural studies. Furthermore, tRNAs adopt a compact threedimensional structure, which makes them resistant to both unfolding and nucleases.
We used this robustness and precise processing to express other structured RNAs in vivo, and designed a generic method using a tRNA as a protective scaffold. We extracted the desired recombinant RNA with high yield and purified it to homogeneity using standard chromatography. We used tools for tagging the RNA with affinity or fluorescent aptamers, and present a scheme for efficiently cleaving off these tags. Overall, the methods described here are in vivo tools for the RNA world that were up to now only available for recombinant proteins.
RESULTS
The tRNA scaffold approach We first tried to directly express structured RNA such as aptamers from vectors previously shown to work with tRNA. The resulting transcripts, however, were heterogeneous and did not accumulate to a substantial amount. Hence it is the tRNA structure, rather than the vector that allows stable expression. Based on this finding we constructed tRNA-RNA fusions, similar to glutathione S-transferase fusions used for protein expression. To retain the three-dimensional structure of the tRNA that is recognized by cellular factors, it was necessary to keep the acceptor, TCC and D stem-loops (Fig. 1a) . This left the anticodon stem as a region for inserting the desired RNA. The resulting RNA chimeras are expected to be recognized by tRNA processing enzymes. Indeed, bacteria naturally produce such a tRNA chimera, transfer-messenger RNA (tmRNA), involved in trans-translation, a rescue mechanism for ribosomes trapped on defective messenger RNA 16 . tmRNA carries a tRNA-like domain 17 with a large, complex structure inserted in the lower stem. Since tmRNA is known to be efficiently processed by tRNAspecific factors, we assumed that an artificially engineered chimera using such a tRNA scaffold would be similarly handled by bacterial cells, in much the same way as intron-containing tRNAs are processed in eukaryotes.
We therefore constructed various plasmids for expressing such recombinant RNA. We replaced the anticodon stem-loop by a sequence containing restriction sites, designed to maintain the twodimensional structure (Fig. 1b) . We used two tRNA scaffolds: human tRNA Lys 3 and E. coli tRNA Met . We selected these because NMR assignments of both tRNAs have been reported, and they have been shown to be efficiently expressed in a recombinant system 13, 14 . Also, the availability of two different scaffolds is advantageous in cases where RNA misfolding occurs because of spurious complementarity between the tRNA and the inserted sequence. The schematic organization of the corresponding expression vectors is illustrated in Figure 1b (DNA sequence is available in Supplementary Fig. 1 online) . In principle, any structured RNA terminated by a stem could thus be inserted into the tRNA scaffold, including aptamers, ribozymes and viral RNA sequences.
Production and characterization of a tRNA chimera As a test case, we focused on the epsilon sequence of human hepatitis B virus (HBV) 18, 19 . This RNA consists of two stems separated by a bulge on which reverse transcription initiates. We expressed chimeras with both tRNA Lys 3 ( Fig. 1c) and tRNA Met scaffolds. The corresponding RNA (112 nucleotides) is strongly expressed in the recombinant strains, representing about 20% of total RNA and roughly 60% of all small, tRNA-size molecules. The tRNA chimera can be purified by performing RNA 'minipreps' from small-scale overnight cultures. Alternatively, this chimera can be purified on a larger scale by standard chromatography (Fig. 1d) . Typical yields are 10-50 mg of purified RNA per liter. By growing cells in labeled medium, it is possible to enrich the recombinant RNA with stable isotopes, such as 15 N and 13 C and to confirm by NMR that the RNA is correctly folded: the 1 H-15 N transverse relaxation-optimized NMR spectroscopy (TROSY) spectrum of the chimeric RNA (Fig. 2) shows a number of well resolved peaks, indicative of a defined, folded structure. We could unambiguously assign most of these peaks to either the tRNA Lys 3 or the HBV epsilon parts. Additionally, the spectra indicate that the tRNA chimera contains modified nucleotides: they show a number of characteristic shifted resonances ( Fig. 2) : pseudouridine (C), 7-methylguanosine (m 7 G), 4-thiouridine (s 4 U). We observed similar shifted resonances for m 7 G46, T54 and dihydrouridines (data not shown). Hence, in vivo, this fused construct is recognized as a genuine tRNA by the cell. It is correctly processed to a Anticodon Acceptor stem The leftmost lane corresponds to the total RNA extract and successive fractions are shown from left to right. Various E. coli tRNAs eluted first, followed by small amounts of 5S ribosomal RNA, whereas the tRNA-HBV chimera eluted last, at a NaCl concentration of about 500 mM. After this single purification step, the tRNA chimera is B90% pure, and the final yield is 50 mg/l. single species of defined length and is modified at expected sites by structure-specific enzymes. Modified nucleotides are known to stabilize the tertiary fold of tRNA, and some of them (for example, s 4 U at position 8) can provide convenient reactive groups for covalently attaching fluorescent labels or immobilizing RNA on solid support 20 .
Applicability of the tRNA scaffold approach We evaluated the general applicability of the method by constructing a series of chimeras and testing their expression in vivo.
We selected diverse inserts, varying in size, topology of the secondary structure, biological origin and function (Fig. 3) , and tested over twenty such constructs, corresponding to chimeras ranging from 74 to 376 nucleotides in length ( Fig. 3 and Supplementary  Fig. 2 online) . For inserts corresponding to structured RNA domains, all the chimera were efficiently expressed and processed to a product of defined length (Fig. 4a) . This was independent of the origin of the RNA insert: artificial, viral, bacterial and human sequences were all efficiently produced, and both branched and nested stem-loop structures were apparently well expressed by the system (yields are given in Supplementary Table 1 online). Some inserts nevertheless were not expressed; for instance, a construct containing the template region of the human telomerase RNA yielded no detectable product. This is possibly because it contained single-stranded regions, which led to nuclease degradation in vivo. Longer inserts also gave smaller yields, suggesting that complex domains might occasionally misfold and get degraded. To minimize this problem, we screened all tentative constructs by computational prediction of their twodimensional structure.
To test the function of these recombinant molecules, we first analyzed a number of ligand-binding RNAs, such as the aptamer selected against sephadex 21 ( Supplementary Fig. 2 ). The corresponding RNA could be bound to sephadex G100, directly from whole cell extracts and then eluted with soluble dextran (Fig. 4b) . 
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We obtained similar results with aptamers selected against streptavidin 22 or malachite green 23 ( Supplementary Fig. 3 online). We also tested the ability of several recombinant constructs to spontaneously self-assemble and form oligomers: the dimerization initiation site of HIV-1 genomic RNA 24 induces dimerization of the corresponding chimera ( Supplementary Fig. 4 online), as in the viral context. We obtained similar results with the chimera containing the pre-head RNA of bacteriophage j29 ( Supplementary  Fig. 2 ), a structural RNA that self-assembles into a ring structure required for packaging the viral DNA 25, 26 . We performed all the above assays using the entire tRNA scaffold chimeras, indicating that within the tRNA context, the inserted RNAs are correctly folded and functional.
Affinity tags and pull-down assay
To enhance the capabilities of the system and streamline purification, we constructed expression vectors allowing the expression of tripartite chimeras containing both a sephadex aptamer-based affinity tag and the RNA of interest inserted in the tRNA scaffold. We made combined constructs for duck and human HBV epsilon RNA (Fig. 3c) , and for an E. coli 23S rRNA fragment (Supplementary Fig. 2 ) and used the sephadex affinity tag to purify the expressed RNA directly from cell lysates under native conditions, in the presence of proteins (Fig. 4b) . As the tRNA chimeras are folded correctly and are functional within cells, they can be used for in vivo studies. By immobilizing RNA chimeras on the affinity matrix, it is possible to perform specific pull-down assays, for example, the specific binding of ribosomal protein L20 to its target site on the 23S rRNA 27 (Fig. 4c) . We also derived similar constructs with a different topology from the streptavidin aptamer ( Supplementary Fig. 2 ).
Release of the RNA insert from the tRNA scaffold Although for some studies, using the entire RNA chimera might be acceptable or even beneficial, in other cases it might be preferable to cleave the desired RNA off the scaffold. We considered several strategies: using either a dedicated ribozyme or DNAzyme, or cleaving with RNase H using a pair of guide DNA oligonucleotides. Dual cis-acting ribozyme constructs have been used for in vitro transcribed RNA, but this approach is not compatible with the tRNA scaffold topology 28 . In our hands, the method that worked best is RNase H cleavage (Fig. 4d) . It produces a defined product in a quantitative manner; furthermore, guide oligonucleotides for RNase H cleavage are targeted against the constant part of the scaffold and hence, the same pair can be used for all constructs. Previous reports of specific RNA cleavage using RNase H used modified DNA nucleotides 29 to improve specificity. In the present case, we used standard DNA oligonucleotides and obtained a single defined product. To test the yield and purity using this method, we made a large scale preparation, using a tRNA chimera carrying the bacterial 16S ribosomal RNA A-site ( Supplementary Fig. 2 ). We obtained B0.8 mmole of doubly labeled RNA from 2 l of 15 N, 13 C labeled medium. The recombinant product was 33 nucleotides long, with cleavage sites located at the junction of the cloverleaf structure (Fig. 5) . This could be a consequence of the (G+C)-richness of the top of the anticodon-like stem, which would resist strand displacement by the ends of the DNA oligonucleotides. We analyzed this purified labeled RNA by gel electrophoresis ( Supplementary Fig. 5 online) and by NMR. A typical 15 N-1 H experiment is shown in Figure 5 , revealing the N-H imino groups involved in base pairing. The NMR spectrum shows a unique set of peaks, direct evidence that a single product with a unique conformation is present in the sample. It also shows the presence of one A Á U and ten to eleven G Á C base pairs, in keeping with the predicted secondary structure. We have now successfully applied this RNase H cleavage strategy to six different constructs with the same guide DNA oligonucleotides (data not shown). In all cases, we observed quantitative cleavage, suggesting that it is a broadly applicable method.
DISCUSSION
Here we demonstrate that it is possible to use our tRNA scaffold approach to express various RNA chimeras. The bacterial machinery recognizes and processes these constructs to single species 
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which accumulate stably within the transformed cells. This demonstrates that the tRNA structure is robust and can accommodate and protect RNA inserts of diverse sizes and structures (Fig. 3) . In all tested cases, the recombinant RNA folded and were functional, even within the chimera. The tRNA scaffold approach is thus a broadly applicable strategy for producing large quantities of virtually any structured RNA fragment. The procedures are all straightforward, involving only standard and parallelizable techniques. Construction of the recombinant expression plasmids is extremely simple: for small RNA inserts, it suffices to ligate a pair of complementary DNA oligonucleotides in the selected vector. It should thus be possible to produce libraries of relevant RNA fragments, such as aptamers or noncoding RNA, for systematic functional analyses. Several RNA fragments produced and purified in this work are of major pharmacological interest: domain III of hepatitis C virus internal ribosome entry site, the epsilon sequence of human and duck HBV viruses, HIV-1 genomic RNA fragments, domains CR4-CR5 and H/ACA of human telomerase RNA, and antibiotic binding regions of bacterial ribosomal RNA (constructs are shown in Supplementary Fig. 2 ). Tens of milligram quantities of pure and stable RNA could thus be reproducibly obtained from liter-scale cultures. Such amounts are required to perform largescale screening of pharmacologically active compounds targeting RNA or for large-scale production of 'therapeutic' RNA constructs. Screening for ligands specific of these RNA targets using flowinjection NMR 30 is presently underway.
Generic purification procedures using affinity tags should open the way to a new range of applications: systematic structural approaches, both by NMR and by crystallography, high-throughput parallel studies of RNA-protein interactions and combinatorial strategies. Also, new in vivo approaches should now be possible, such as coexpression of RNA-protein complexes. The recombinant RNA approach is also cost-effective, which is important for studies requiring incorporation of expensive stable isotopes, and for applications requiring large amounts of material, such as mediumand high-throughput screening of RNA-specific ligands. For the latter applications, however, cleavage of the target RNA from the scaffold is likely to be required to eliminate tRNA-binding ligands, at least in secondary screens. With the availability of fluorescent tags and an efficient generic cleavage system, the complete spectrum of tools available for recombinant proteins is now also available for RNA.
METHODS
Vector construction. We derived all vectors from pBSTNAV 12 , by assembling synthetic overlapping oligonucleotides (purchased from Eurogentec). We constructed six such vectors, based on either human tRNA Lys 3 or E. coli tRNA Met , using either no tag, a streptavidin or a sephadex aptamer tag. We subsequently used these vectors for inserting various DNA oligonucleotides coding for the RNA fragments using a similar strategy (Fig. 1b) . We verified the DNA sequence of all plasmid constructs by sequencing (Millegen). The cloning sites were EagI (5¢) and SacII (3¢) for the naked scaffold vectors, and SalI (5¢) and AatII (3¢) for the aptamer-containing vectors ( Supplementary Fig. 1 ). These specific combinations of restriction sites ensured that the corresponding RNA transcript folded into an anticodon-like stem and loop structure.
RNA expression and purification. We used freshly transformed E. coli cells (strain JM101Tr) in all expression experiments. This proved crucial for maintaining a high expression level from the constitutive lpp promoter. For controlling expression levels, we performed RNA 'minipreps' on 5 ml of overnight cultures grown in LB medium. We pelleted and resuspended these cells in 50 ml of 10 mM magnesium acetate, 1 mM Tris-HCl, pH 7.4 (buffer L). We extracted the suspension with saturated phenol, ethanolprecipitated the aqueous phase and analyzed the RNA contents by 8% polyacrylamide-urea gel electrophoresis. We visualized bands by UV shadowing. For large-scale production (1 l cultures), RNA accumulation was optimal after 12-18 h of growth after inoculation, in the early stationary phase, and we obtained higher yields with richer media. We thus grew most cultures overnight in 2Â TY medium, starting from freshly transformed cells. As for minipreps, we pelleted and resuspended cells in 8 ml of buffer L. We added one volume of saturated phenol to the tube, and gently agitated it for 1 h at room temperature (18-22 1C) , to ensure complete cell lysis. After centrifugation, we collected the aqueous phase and added one-fifth volume equivalent of 5 M NaCl to precipitate high-molecular-weight nucleic acids, which we then removed by centrifugation. We ethanol-precipitated the supernatant containing small RNA, allowed the pellet to dry and then dissolved it in 20 mM sodium phosphate, pH 7.0 (Buffer A). We loaded the RNA extract on an ion-exchange column (Q-Hiload; Amersham) equilibrated in buffer A and eluted with a 0-1 M NaCl gradient in the same buffer. We analyzed fractions by electrophoresis on 8% urea-acrylamide gels, and pooled and ethanolprecipitated fractions containing the desired RNA. Yields were 10-50 mg of purified RNA per liter, with a purity of 80-90%, depending on the construct, after this single chromatography step. Whenever required, we could achieve further purification by gel filtration: we dissolved the RNA in 20 mM sodium phosphate, 100 mM NaCl, pH 7.0, loaded it on a Superdex-75 column (Amersham) equilibrated in the same buffer and eluted it at 0.5 ml/min. We pooled and ethanol-precipitated fractions containing the RNA. For structural studies, we dissolved the purified RNA in water, dialyzed it and lyophilized it.
NMR spectroscopy. We dissolved purified RNA samples in 300 ml of 10% 2 H 2 O-90% H 2 O (final concentration 1 mM). We acquired spectra at 15 1C (288 K) on a 600 MHz Bruker Avance spectrometer. We recorded 1 H-15 N TROSY and heteronuclear multiple quantum correlation (HMQC) experiments as previously described 31 .
Affinity purification. We pelleted an overnight culture (10 ml) of the overproducing strain. We suspended cells in 400 ml of 50 mM potassium phosphate, 5 mM MgCl 2 , 100 mM NaCl, pH 7.5 (Buffer A) and disrupted them by sonication. We removed debris by centrifugation and incubated the supernatant with either streptavidin-coated iron oxide magnetic beads (Dynal) or Sephadex G100 (Roche) suspended in buffer A. We washed the beads three times with buffer A and performed elution using 200 ml of buffer A supplemented either with 5 mM D-biotin or with 200 mg/ml of soluble dextran (M r 1,500; Fluka), for the strepatividin and sephadex aptamer constructs, respectively.
Pull-down assay. We extracted the tRNA chimera (tRNAsephadex aptamer; tRNA-sephadex aptamer-23S rRNA) as
